Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

被引:21
|
作者
Pastori, Daniele [1 ,2 ]
Farcomeni, Alessio [3 ]
Saliola, Mirella [1 ]
Del Sole, Francesco [1 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
Lip, Gregory Y. H. [2 ,4 ]
机构
[1] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Clin Med 1, Atherothrombosis Ctr, Rome, Italy
[2] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[3] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Anticoagulation; Vitamin K antagonists; Time in therapeutic range; Cardiovascular events; PROTON PUMP INHIBITORS; ANTICOAGULATION CONTROL; ORAL ANTICOAGULATION; WARFARIN; QUALITY; RISK; EFFICACY; ASPIRIN; STROKE; SAFETY;
D O I
10.1016/j.ejim.2018.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. Methods: Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently >= 70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently < 70% (n = 567). Results: In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA(2)DS(2)VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. Conclusion: A decrease of TTR < 70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 50 条
  • [31] Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation
    Cangemi, Roberto
    Pignatelli, Pasquale
    Carnevale, Roberto
    Corazza, Gino Roberto
    Pastori, Daniele
    Farcomeni, Alessio
    Basili, Stefania
    Davi, Giovanni
    Ferro, Domenico
    Hiatt, William R.
    Licata, Giuseppe
    Lip, Gregory Y. H.
    Loffredo, Lorenzo
    Mannucci, Pier Mannuccio
    Vestri, Annarita
    Violi, Francesco
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 3241 - 3247
  • [32] Therapeutic management of non-valvular atrial fibrillation. Update 2013
    Bode, K.
    Sommer, P.
    Bollmann, A.
    Hindricks, G.
    [J]. HERZ, 2013, 38 (07) : 743 - 755
  • [33] Copeptin levels are associated with cardiovascular events in patients with non valvular atrial fibrillation
    Lang, S.
    Ederhy, S.
    Boyer-Chatenet, L.
    Haddour, N.
    Soulat-Dufour, L.
    Fleury, G.
    Baudin, B.
    Raffi, H.
    Boccara, F.
    Cohen, A.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 : 737 - 737
  • [34] Achievement of international normalized ratio therapeutic range among chronic non-valvular atrial fibrillation patients treated with warfarin
    Harley, CR
    Shetty, S
    Hauch, O
    Wygant, G
    Riedel, AA
    Nelson, M
    [J]. CIRCULATION, 2004, 109 (20) : E271 - E271
  • [35] Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
    Atwater, Brett D.
    Guo, Jennifer D.
    Keshishian, Allison
    Delinger, Rachel
    Russ, Cristina
    Rosenblatt, Lisa
    Jiang, Jenny
    Yuce, Huseyin
    Ferri, Mauricio
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (01) : 1 - 10
  • [36] Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation
    Brett D. Atwater
    Jennifer D. Guo
    Allison Keshishian
    Rachel Delinger
    Cristina Russ
    Lisa Rosenblatt
    Jenny Jiang
    Huseyin Yuce
    Mauricio Ferri
    [J]. Journal of Thrombosis and Thrombolysis, 2024, 57 : 1 - 10
  • [37] Patients Prescribed Warfarin For Active Non-Valvular Atrial Fibrillation, Their Time In The Therapeutic Range (TTR%) And The Recommendations For Novel Anticoagulant Therapy - A Clinical Audit
    Tansey, P.
    Nugent, M.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S57 - S57
  • [38] Time in the Therapeutic Range During Warfarin Therapy in Japanese Patients With Non-Valvular Atrial Fibrillation - A Multicenter Study of Its Status and Influential Factors -
    Okumura, Ken
    Komatsu, Takashi
    Yamashita, Takeshi
    Okuyama, Yuji
    Harada, Masahiko
    Konta, Yoshiyuki
    Hatayama, Toru
    Horiuchi, Daisuke
    Tsushima, Eiki
    [J]. CIRCULATION JOURNAL, 2011, 75 (09) : 2087 - 2094
  • [39] Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
    Samaras, A.
    Vrana, E.
    Kartas, A.
    Rampidis, G.
    Doundoulakis, I.
    Fotos, G.
    Efthimiadis, G.
    Karvounis, H.
    Tzikas, A.
    Giannakoulas, G.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 421 - 421
  • [40] Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
    Athanasios Samaras
    Eleni Vrana
    Anastasios Kartas
    Dimitrios V. Moysidis
    Andreas S. Papazoglou
    Ioannis Doundoulakis
    George Fotos
    Georgios Rampidis
    Dimitrios G. Tsalikakis
    Georgios Efthimiadis
    Haralambos Karvounis
    Apostolos Tzikas
    George Giannakoulas
    [J]. BMC Cardiovascular Disorders, 21